Join the Oncology Voice Network. Join for Free
Role of the MSL in launch preparedness for new products and indications
MSL roles drug launch preparation medical affairs strategy pharmaceutical trends field medical leadership

Role of the MSL in launch preparedness for new products and indications


Share This Article


Summary

Matt Goodwin joins Tom Caravela to discuss the crucial role of MSLs in drug launch preparation and leadership. Matt shares his career journey and insights from his experiences at MAPS. They delve into the training, expectations, and success factors for MSLs during launches, addressing common stressors and establishing key milestones. The conversation highlights common pitfalls and offers advice for MSLs navigating launch phases. They examine the skills and motivation needed for evaluating MSL candidates and discuss future trends in pharma and MSL roles. The episode concludes with a call for listener feedback and subscription.

Matt Goodwin, Vice President Medical Affairs at SC Pharmaceuticals discusses the role of the MSL in preparation and strategy for launch preparedness of new products/indications.

Learn more about…

👉 The importance of preparation and timeline for launch
👉 Training and resources for launch mode
👉 The role of field medical leadership
👉 Milestones and success factors to consider
👉 The stressors to be aware of and anticipate during a launch

Click for Source
MSL roles, drug launch preparation, medical affairs strategy, pharmaceutical trends, field medical leadership

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
No “D”…No Problem: Finding Success WITHOUT a Doctorate
Partner Avatar MSL Talk: Tom Caravela, Greg Auclair

No “D”…No Problem: Finding Success WITHOUT a Doctorate

Podcast
Motivation Means NOTHING…
Partner Avatar MSL Talk: Tom Caravela

Motivation Means NOTHING…

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Article
The Oncology Data Network (ODN): Methodology, Challenges, and Achievements
OVN Avatar Ashley Woolmore , Dirk Arnold , Jean‐Yves Blay , Christian Buske , Alfredo Carrato , Winald Gerritsen , Marc Peeters , Jesus Garcia‐Foncillas , David Kerr

The Oncology Data Network (ODN): Methodology, Challenges, and Achievements

Article
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
OVN Avatar Alyson Haslam, PhD; Vinay Prasad, MD, MPH

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

Article
Loose Regulatory Standards Portend a New Era of Imprecision Oncology
OVN Avatar Ali Raza Khaki

Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Explore OVN